Exelixis initiated with a Peer Perform at Wolfe Research

Wolfe Research analyst Kalpit Patel initiated coverage of Exelixis (EXEL) with a Peer Perform rating and no price target Zanzalintinib is unlikely to fully replenish cabozantinib’s potential lost revenues, the analyst tells investors.